Evonik Industries (EVK) Q3 2024 earnings summary

Executive summary

• Adjusted EBITDA reached €577 million in Q3 2024, up 19% year-over-year, with margin improving to 15–15.1% and sector-leading earnings growth.

• Free cash flow for the first nine months was €701 million, over €400 million higher than the prior year, supporting a targeted 40% cash conversion rate for FY 2024.

• Cost-saving initiatives, business optimization, and realignment in Health Care and Coating & Adhesive Resins are strengthening the earnings profile.

• Innovation strategy focuses on Biosolutions, Circular Economy, and Energy Transition, targeting €1.5 billion in new sales by 2032.

• Portfolio realignment continues, with exits from underperforming businesses to sharpen focus and improve financial KPIs.

Financial highlights

• Q3 2024 sales were €3,832 million, up 2% year-over-year; organic sales growth was 5%, offset by negative currency effects and divestments.

• Adjusted EBIT increased 59% to €322 million; adjusted net income rose 43% to €271 million.

• Free cash flow in Q3 was €357 million, with a conversion rate around 40%.

• CapEx for FY 2024 targeted at around €750–800 million, slightly lower than prior year.

• Net financial debt decreased to €3,286 million at quarter-end, driven by strong cash generation.

Outlook and guidance

• FY 2024 adjusted EBITDA guidance confirmed at €1.9–2.2 billion, underpinned by strong 9M results.

• Free cash flow conversion rate targeted at around 40% for 2024 and 2025.

• Sales expected between €15–17 billion; capex around €750 million.

• Market growth in Nutrition & Care expected at 3–4% in 2025, especially driven by Asia.

• All divisions anticipate higher earnings than previous year; margin expectation higher than at start of year.